Yaşlanma ve Kanser Fizyolojisi–İmmünolojisi–Genetiği

López-Otín C, Blasco MA, Partridge L, et al. The hallmarks of aging. Cell. 2013;153(6):1194-1217

Lash TA, Escobedo MR. Introduction| Clinics in Geriatric Medicine-Volume 34, Issue 3. Elsevier; 2018. p. 17-19.

National Cancer Institute. Cancer Stat Facts: Cancer of Any Site. Surveillance E, and End Results (SEER) Program, 2018–2022. [Internet]. Bethesda, MD: National Cancer Institute; 01/07/2025 tarihinde https://seer.cancer.gov/statfacts/html/all.html adresinden ulaşılmıştır.

Campisi J. Aging, cellular senescence, and cancer. Annual review of physiology. 2013;75(1):685-705

Coppé J-P, Desprez P-Y, Krtolica A, et al. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annual review of pathology: mechanisms of disease. 2010;5(1):99-118

Tuxhorn JA, Ayala GE, Smith MJ, et al. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clinical Cancer Research. 2002;8(9):2912-2923

Montégut L, López-Otín C, Kroemer G. Aging and cancer. Molecular Cancer. 2024;23(1):106

Yu M, Hazelton WD, Luebeck GE, et al. Epigenetic aging: more than just a clock when it comes to cancer. Cancer research. 2020;80(3):367-374

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. cell. 2011;144(5):646-674

Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer cell. 2010;18(1):11-22

Yegnasubramanian S, Haffner MC, Zhang Y, et al. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer research. 2008;68(21):8954-8967

Barba I, Carrillo-Bosch L, Seoane J. Targeting the Warburg effect in cancer: where do we stand? International Journal of Molecular Sciences. 2024;25(6):3142

Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine. 2007;356(2):115-124

Wood EL, Adibi M, Qiao W, et al. Local tumor bed recurrence following partial nephrectomy in patients with small renal masses. The Journal of urology. 2018;199(2):393-400

Wolfe AR, Prabhakar D, Yildiz VO, et al. Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection. Cancer medicine. 2020;9(13):4711-4723

Weiskopf D, Weinberger B, Grubeck‐Loebenstein B. The aging of the immune system. Transplant international. 2009;22(11):1041-1050

Goronzy JJ, Weyand CM. Mechanisms underlying T cell ageing. Nature Reviews Immunology. 2019;19(9):573-583

Feng E, Balint E, Poznanski SM, et al. Aging and Interferons: Impacts on Inflammation and Viral Disease Outcomes. Cells. 2021;10(3).10.3390/cells10030708

Akbar AN, Henson SM. Are senescence and exhaustion intertwined or unrelated processes that compromise immunity? Nature Reviews Immunology. 2011;11(4):289-295

Franceschi C, Bonafè M, Valensin S, et al. Inflamm‐aging: an evolutionary perspective on immunosenescence. Annals of the new York Academy of Sciences. 2000;908(1):244-254

Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nature immunology. 2002;3(11):991-998

Nishijima TF, Muss HB, Shachar SS, et al. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis. Cancer treatment reviews. 2016;45:30-37

Balar AV, Castellano D, O'Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. The Lancet Oncology. 2017;18(11):1483-1492

Martincorena I, Campbell PJ. Somatic mutation in cancer and normal cells. Science. 2015;349(6255):1483-1489

Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339(6127):1546-1558

Abida W, Cyrta J, Heller G, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proceedings of the National Academy of Sciences. 2019;116(23):11428-11436

Abeshouse A, Ahn J, Akbani R, et al. The molecular taxonomy of primary prostate cancer. Cell. 2015;163(4):1011-1025

Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540-556. e25

Pal S, Tyler J. Epigenetics and aging. Sci Adv 2: e1600584. 2016.

Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. New England Journal of Medicine. 2014;371(26):2488-2498

Liu X, Sato N, Shimosato Y, et al. CHIP‐associated mutant ASXL1 in blood cells promotes solid tumor progression. Cancer Science. 2022;113(4):1182-1194

Chan TA, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Annals of Oncology. 2019;30(1):44-56

Erbe R, Wang Z, Wu S, et al. Evaluating the impact of age on immune checkpoint therapy biomarkers. Cell reports. 2021;36(8)

McGrail D, Pilié P, Rashid N, et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Annals of Oncology. 2021;32(5):661-672

Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Molecular cancer therapeutics. 2017;16(11):2598-2608

Cristescu R, Mogg R, Ayers M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy. Science. 2018;362(6411):eaar3593

Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. Journal of clinical oncology. 2014;32(24):2595-2603

Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. Journal of clinical oncology. 2011;29(25):3457-3465

Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High‐Age Patients (CRASH) score. Cancer. 2012;118(13):3377-3386

Ploussard G, Daneshmand S, Efstathiou JA, et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. European urology. 2014;66(1):120-137